Does Medicare Advantage Cover Zetia (Ezetimibe)?

How Medicare Advantage Prescription Drug Plans Handle Ezetimibe

Generic ezetimibe 10 mg is classified as a preferred generic on the majority of Medicare Advantage Prescription Drug (MA-PD) formularies filed with the Centers for Medicare & Medicaid Services (CMS). CMS requires every Part D plan to cover at least two drugs per therapeutic class, and the HMG-CoA reductase inhibitor/cholesterol absorption inhibitor category almost always includes ezetimibe given its FDA-approved indication as an adjunct to diet and statins for lowering LDL cholesterol [1]. Because generic pricing has dropped below $15 per month at most pharmacies, plans have little financial incentive to restrict access.

Brand-name Zetia occupies a different position. Plans that still list it typically place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), resulting in copays of $40 to $100 per fill. Some plans have removed brand Zetia entirely and direct members to the generic. The CMS Medicare Part D formulary guidance permits this substitution as long as a therapeutically equivalent option remains available [2].

Each plan year, MA-PD sponsors submit formulary files to CMS for review under 42 CFR § 423.120. Beneficiaries can verify their specific plan's coverage using the Medicare Plan Finder tool. Tier placement, quantity limits, and prior authorization flags may differ across carriers such as UnitedHealthcare, Humana, Aetna, and Cigna, even within the same county [3].

Ezetimibe's Clinical Profile and Why Plans Cover It

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by approximately 54% [4]. The drug lowers LDL cholesterol by 15% to 20% as monotherapy and by an additional 23% to 24% when added to ongoing statin therapy, according to pooled trial data published in the American Heart Association's journal Circulation [5].

The cardiovascular outcomes evidence rests on the IMPROVE-IT trial (N=18,144), which randomized post-acute-coronary-syndrome patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin plus placebo. Over a median 6 years of follow-up, the combination arm achieved a 2-percentage-point absolute reduction in the primary composite endpoint (cardiovascular death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke): 32.7% vs. 34.7%, HR 0.936, 95% CI 0.89 to 0.99, P=0.016 [6].

This matters for formulary decisions. The 2018 AHA/ACC cholesterol guideline incorporated IMPROVE-IT data into its recommendation for adding ezetimibe as second-line therapy when LDL remains ≥70 mg/dL on maximally tolerated statin therapy [7]. CMS-contracted pharmacy benefit managers use guideline alignment as a factor in formulary tier placement, which partly explains ezetimibe's favorable positioning on most Part D plans [8].

Prior Authorization Requirements for Zetia on Medicare Advantage

Prior authorization (PA) for generic ezetimibe is uncommon. Fewer than 12% of MA-PD plans required PA for generic ezetimibe in the 2025 plan year, based on CMS formulary file analysis [9]. When PA is required, the typical criteria include:

• A documented diagnosis of primary hyperlipidemia (ICD-10 E78.0 through E78.5) or homozygous familial hypercholesterolemia (HoFH)
• Current use of, intolerance to, or contraindication for at least one moderate-to-high-intensity statin [10]
• LDL cholesterol above the patient's risk-based goal on current lipid-lowering therapy

Brand Zetia triggers PA more frequently. Plans that still carry it often impose a "generic first" or "generic available" edit. The prescriber must document a clinical reason why the generic formulation cannot be used (true allergy to an inactive ingredient, for instance). Documenting simple preference is not sufficient under CMS coverage determination standards [11].

PA turnaround time is governed by federal regulation: 72 hours for standard requests and 24 hours for expedited requests where delay could jeopardize the enrollee's life or health, per 42 CFR § 423.568 [12].

Step Therapy: Do You Need to Try a Statin First?

Some Medicare Advantage plans apply step therapy protocols requiring documentation that a statin was tried (or is contraindicated) before covering ezetimibe. This practice is permitted under the CMS Part D step therapy rule finalized in the 2019 Final Rule (CMS-4180-F), which allows Part D sponsors to impose step therapy if they meet clinical-evidence and notice requirements [13].

In practice, this rarely delays therapy. Most patients prescribed ezetimibe have already been on a statin, since ACC/AHA guidelines position statins as first-line pharmacotherapy for atherosclerotic cardiovascular disease risk reduction [7]. The prescriber typically documents the statin history in the electronic health record, and the plan's pharmacy benefit manager accepts that documentation to satisfy the step.

Patients with documented statin intolerance (myalgia, rhabdomyolysis risk, hepatotoxicity) can bypass step therapy entirely. A 2014 meta-analysis in the European Heart Journal found that approximately 7% to 29% of statin users report muscle-related symptoms, though rechallenge studies suggest true pharmacological intolerance affects closer to 7% to 10% [14]. Documenting the specific adverse reaction and the statin(s) tried gives the strongest basis for a step-therapy override.

For patients with homozygous sitosterolemia, ezetimibe carries a standalone FDA indication and step therapy requiring a statin trial does not apply, since statins are not indicated for that condition [15].

Understanding Formulary Tiers and Cost Sharing

Medicare Part D plans use a tiered structure that directly determines out-of-pocket costs. The standard tier framework for ezetimibe looks like this:

Tier 1 (Preferred Generic): Most MA-PD plans place generic ezetimibe here. Copays range from $0 to $10. Plans with $0 preferred generic tiers, such as certain UnitedHealthcare AARP and Humana plans, eliminate cost sharing entirely for ezetimibe during the initial coverage period [16].

Tier 2 (Generic): Some plans place ezetimibe on a non-preferred generic tier with copays of $5 to $20. This still represents minimal financial burden for most beneficiaries.

Tier 3 or 4 (Brand): Brand Zetia, when listed, sits here with copays of $40 to $100 or coinsurance of 25% to 50%. At a list price near $380, coinsurance in the coverage gap phase can be significant even after the manufacturer discount applied under the Inflation Reduction Act's Part D redesign [17].

The 2025 Part D redesign capped annual out-of-pocket spending at $2,000, which protects beneficiaries who reach catastrophic coverage. For a drug as inexpensive as generic ezetimibe, most patients will never approach the cap from this medication alone [18].

Beneficiaries can request a tier exception if they believe their plan has placed ezetimibe on an inappropriately high tier. The prescriber must submit a supporting statement indicating that the lower-tier alternatives within the same class are ineffective, contraindicated, or likely to cause adverse effects [19].

How to Appeal a Medicare Advantage Denial of Ezetimibe

Coverage denials follow a structured appeals process defined by 42 CFR Part 423 Subpart M [12]. The steps are sequential. Each level must be exhausted before moving to the next.

Level 1: Plan Redetermination. The enrollee or prescriber files a written request within 60 days of the denial. The plan has 7 calendar days (72 hours for expedited) to issue a decision. Include the denial letter, clinical notes showing diagnosis and statin history, and relevant lab results (LDL, total cholesterol, triglycerides).

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case automatically forwards (or can be manually submitted) to the IRE, currently MAXIMUS Federal Services. MAXIMUS reviews the clinical evidence independently. Turnaround is 7 days standard, 72 hours expedited [20].

Level 3: Office of Medicare Hearings and Appeals (OMHA). Available if the amount in controversy meets the threshold ($185 in 2025) and the IRE upheld the denial. An Administrative Law Judge conducts a hearing, often by telephone.

Level 4: Medicare Appeals Council. Reviews ALJ decisions.

Level 5: Federal District Court. Available if the amount in controversy exceeds $1,850 (2025 threshold).

For generic ezetimibe, most legitimate coverage disputes resolve at Level 1 or Level 2. The denial is often a claims-processing error or missing documentation rather than a true clinical coverage refusal. A 2023 HHS Office of Inspector General report found that MA plans overturned 82% of prior authorization denials when beneficiaries filed a first-level appeal, underscoring the value of pursuing even a single appeal step [21].

Ezetimibe vs. Other Non-Statin Options on Medicare Formularies

Ezetimibe is not the only non-statin cholesterol-lowering drug covered by Part D, but it is the most accessible in terms of cost and prior authorization burden.

Ezetimibe vs. PCSK9 inhibitors. Alirocumab (Praluent) and evolocumab (Repatha) lower LDL by 50% to 60% but cost $5,000 to $14,000 annually and carry strict PA criteria on nearly all Part D plans [22]. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced the composite cardiovascular endpoint by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) but at substantially greater cost per quality-adjusted life year [23].

Ezetimibe vs. bempedoic acid. Bempedoic acid (Nexletol) received FDA approval in February 2020 and targets the same cholesterol synthesis pathway as statins but upstream of HMG-CoA reductase. The CLEAR Outcomes trial (N=13,970) showed a 13% relative reduction in MACE among statin-intolerant patients (HR 0.87, 95% CI 0.79 to 0.96, P=0.004) [24]. Brand cost sits near $500 per month, and PA is required on most formularies.

Ezetimibe vs. inclisiran. Inclisiran (Leqvio), a twice-yearly injectable siRNA, lowers LDL by approximately 50% but carries a list price of roughly $3,250 per injection and requires in-office administration covered under Part B rather than Part D [25].

Generic ezetimibe's combination of proven cardiovascular benefit, low cost, oral dosing, and minimal PA burden makes it the first-line non-statin add-on for most Medicare beneficiaries. The 2022 ACC Expert Consensus Decision Pathway explicitly positions ezetimibe as the preferred non-statin before escalating to PCSK9 inhibitors or bempedoic acid [26].

Ezetimibe-Statin Combination Products and Medicare

Two fixed-dose combinations containing ezetimibe are FDA-approved: ezetimibe/simvastatin (formerly marketed as Vytorin) and ezetimibe/atorvastatin (Liptruzet, discontinued). Generic ezetimibe/simvastatin is available in multiple dose strengths (10/10, 10/20, 10/40, 10/80 mg) and appears on Part D formularies alongside standalone ezetimibe [27].

For patients already taking simvastatin, switching to the combination tablet may improve adherence by reducing pill count. A retrospective cohort study in the Journal of Managed Care Pharmacy (N=8,862) found that fixed-dose combination users had 12% higher medication adherence at 12 months compared with patients taking the two drugs separately [28]. Plans may prefer separate generics on cost grounds, however, so prior authorization can apply to the combination product even when both components are covered individually.

Special Populations: Dual-Eligible and Low-Income Subsidy Beneficiaries

Beneficiaries who qualify for both Medicare and Medicaid (dual-eligible) or who receive the Part D Low-Income Subsidy (LIS, also called "Extra Help") face reduced or eliminated cost sharing for ezetimibe. Full LIS beneficiaries pay no more than $4.50 for a generic and $11.20 for a brand-name drug in 2025 per fill [29]. Since generic ezetimibe often costs less than $10 at retail, LIS beneficiaries may effectively pay $0 to $4.50.

Dual-eligible beneficiaries are auto-enrolled into a benchmark Part D plan if they do not actively choose one. These benchmark plans must cover all drug classes required by CMS, and ezetimibe falls within a covered class [30]. If a dual-eligible beneficiary's assigned plan does not cover ezetimibe (rare but possible), they can request a plan change during any month of the year without waiting for the Annual Enrollment Period.

Manufacturer Copay Cards and Medicare: Why They Don't Apply

Federal anti-kickback statute 42 U.S.C. § 1320a-7b(b) prohibits pharmaceutical manufacturers from offering copay assistance to beneficiaries enrolled in any federally funded healthcare program, including Medicare Part D and Medicare Advantage [31]. Organon (Zetia's current manufacturer) offers a savings card for commercially insured patients, but Medicare beneficiaries are ineligible.

Alternatives include independent charitable patient assistance foundations, state pharmaceutical assistance programs (SPAPs), and the Part D Extra Help program mentioned above. Because generic ezetimibe costs under $15 per month at most pharmacies, financial barriers are minimal for the generic formulation even without supplemental assistance [32].